MAX BioPharma, Inc.

MAX BioPharma announces key update on its anti-fibrotic and anti-inflammatory oxysterol drug candidate that inhibits MASH, atherosclerosis, and fat tissue inflammation. #oxysteroltherapeutics #mash #atherosclerosis #inflammation #fibrosis https://lnkd.in/guj9xp6k

We are proud to announce the publication of our paper that demonstrates for the first time, in a humanized mouse model, that an oxysterol-based drug candidate, Oxy210, with anti-inflammatory and anti-fibrotic properties, ameliorates atherosclerosis that is the number one killer of people with fatty liver and its more advanced form, metabolic dysfunction-associated steatohepatitis (MASH). Fatty liver/MASH is the pandemic of our century that leads to a multitude of disorders, and may lead to liver failure and liver cancer. We previously reported that Oxy210 inhibits MASH and reduces cholesterol levels and inflammatory cytokines. We propose that Oxy210 is an ideal and novel drug candidate for targeting both MASH and atherosclerosis based on its anti-inflammatory, anti-fibrotic and cholesterol-lowering properties that target not just one, but multiple cellular and molecular drivers of atherosclerosis and MASH. Oxy210 has a unique mechanism of action that is distinct from that of the dozens of failed drug candidates that were being developed for targeting MASH. #maxbiopharma #oxysteroltherapeutics #oxysterol #atherosclerosis #mash #fattyliver #antiinflammatory #antifibrotic #cholesterollowering  https://lnkd.in/gbhhezGM

We thank the Southern California Biomedical Council (SoCalBio) team for having us at this year’s SoCalBio 26th Annual Investor Conference where MAX BioPharma shared key updates for OxyFuse-133 for spinal fusion and Oxy210 for treating metabolic dysfunction-associated steatohepatitis (MASH). As part of its Series A raise, the company is seeking institutional investors to initiate Phase 1 studies in 2025. #socalbio #longla #maxbiopharma #oxysteroltherapeutics #spinefusion #mash

Our CEO, Farhad Parhami, Ph.D., M.B.A., will be presenting at the 4th Annual TGF-beta Targeted Drug Development Summit taking place on October 15-17. https://lnkd.in/gfp_9V9r

https://lnkd.in/gfp_9V9r

Greatly appreciated being recognized among other great businesses started by successful and brilliant UCLA alumni. And an honor receiving this MAX BioPharma's certificate together with Co-Founder and CEO of Metaba, Philip Sell, who accepted the certificate on behalf of Metaba. Congratulations to all the alumni and businesses that were recognized last night at this very well-organized event. Philip Sell Jaejin (Joey) Lee Eric Michel, PhD Richard Balagtas

UCLA Alumni Association presents this year's 2024 Bruin Business 100! Our founder, Farhad Parhami, Ph.D., M.B.A., is proud to be recognized as part of the Bruin Business 2024 honorees. Check out the full list of celebrated businesses here: https://t.co/S15dJgEvSJ  #BruinBusinesses #UCLA #maxbiopharma

Came across this great read about the use of metabolomics in drug discovery. It is definitely a powerful tool that complements our traditional ways to examine and evaluate the favorability of drug candidates for therapeutic development and identify their mechanisms of action. At MAX BioPharma, in collaboration with scientists at Metaba, we have started to apply metabolomics in our drug discovery efforts and development of our oxysterol drug candidates for multiple indications including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), atherosclerosis, and chronic inflammation. Large amounts of insightful information are derived from metabolomic studies, and hopefully soon we will begin to share our findings with the scientific community. #Oxysterol #Metabolomics #NASH #IPF #Atherosclerosis #Cysticfibrosis #Inflammation #MAXBioPharma #Metaba Philip Sell Metaba Jaejin (Joey) Lee Eric Michel, PhD https://lnkd.in/g_xdSU5Q

Obesity is a condition that results in low grade chronic inflammation in many tissues and organs in the body. Chronic inflammation is recognized as the underlying cause of many diseases, especially those associated with aging (inflammaging). At MAX BioPharma, we are developing a novel small molecule oxysterol, Oxy210, that inhibits inflammation in multiple tissues and organs in mouse models of metabolic disorder, including in the liver, fat, and artery wall. This orally bioavailable oxysterol has a favorable safety profile and is highly scalable and inexpensive to produce. We are hopeful that Oxy210 will have a robust positive impact on diseases that involve chronic inflammation. In collaboration with scientists at Metaba we are identifying metabolic changes induced by Oxy210 that could at least partially explain its mechanism of action. #Oxysterol #Oxy210 #Obesity #Inflammation #MAXBioPharma #Metaba #Inflammaging Philip Sell Jaejin (Joey) Lee Metaba

MAX BioPharma's Oxysterol Therapeutics Platform technology continues to provide insights into the potential of our drug candidates in additional disease areas, most recently in cystic fibrosis (CF). CF is a rare but devastating disorder that is often diagnosed in childhood and worsens with time. Unfortunately, individuals with CF are of gravely poor health, and although some of the new CFTR modulators when administered in a triple combination have had some clinical benefits, their effects on improving quality of life have been quite modest. We hope that we can provide some hope with our drug candidates that have potent anti-inflammatory and anti-fibrotic activities and are showing benefits in preclinical models of CF. #Oxysterol #Cysticfibrosis #Inflammation #CFF #Metaba #MAXBIOPHARMA